{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:11Z","timestamp":1786736231250,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijc.ijc_732_18","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T09:10:17Z","timestamp":1567069817000},"page":"274","source":"Crossref","is-referenced-by-count":5,"title":["TSC1\/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study"],"prefix":"10.4103","volume":"56","author":[{"given":"LinuA","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowhar","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.263046-1","first-page":"335","article-title":"Targeted therapy for metastatic renal cell carcinoma","author":"Afriansyah","year":"2016","journal-title":"Acta Med Indones"},{"key":"key-10.4103\/0019-509X.263046-2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CE.S98687","article-title":"Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy","author":"Buti","year":"2016","journal-title":"Core Evid"},{"key":"key-10.4103\/0019-509X.263046-3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma","author":"Kwiatkowski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0019-509X.263046-4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1442-2042.2002.00418.x","article-title":"Recurrence of renal cell carcinoma more than 5 years after nephrectomy","author":"Uchida","year":"2002","journal-title":"Int J Urol"},{"key":"key-10.4103\/0019-509X.263046-5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/0019-509X.263046-6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","article-title":"The biology behind mTOR inhibition in sarcoma","author":"Wan","year":"2007","journal-title":"Oncologist"},{"key":"key-10.4103\/0019-509X.263046-7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1096\/fj.01-0658com","article-title":"Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling","author":"Humar","year":"2002","journal-title":"FASEB J"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:13Z","timestamp":1786732753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_732_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"alternative-id":["263046"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_732_18","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}